Cancer Biopsy Market Report and Forecast 2025-2034
Description
The cancer biopsy market size in the major markets was valued at USD 28.70 Billion in 2024, driven by the incidence of cancer cases across the 7 major markets. The market is expected to grow at a CAGR of 13.20% during the forecast period of 2025-2034, with the values likely to rise from USD 99.16 Billion by 2034.
Cancer Biopsy: Introduction
Cancer Biopsy is a type of diagnostic method to detect the presence of a tumour in a body part. It is done by removing a piece of tissue or a sample of cells from the body to test externally in a lab. If cancer exists, a biopsy can help in the determination of its grade. Doctors mostly prescribe it if a patient shows underlying signs of cancer like weakness or fatigue.
After taking the tissue sample, it is sent to a laboratory where it can be chemically treated or frozen and sliced into thin sections. These sections are later placed on glass slides and studied under a microscope. There are different types of biopsies like needle biopsies, skin biopsies, endoscopic biopsies, and others.
Cancer Biopsy Market Analysis
Cancer is one of the most fatal diseases, affecting a substantial portion of the population. As there has been significant emphasis on treatment, early diagnosis plays a critical role in decreasing the number of mortalities related to it. Therefore, the cancer biopsy market demand has increased over the years.
Over the years, liquid biopsy has been a preferred method of detection when compared to conventional technology. This can be attributed to its safe, non-invasive, and easily recurring process. With a vision to expand the potential of liquid biopsy to detect and monitor cancer, researchers at the AACR annual meeting 2023 presented a study of an MCED test which utilizes a new platform to analyze DNA methylation. This new platform captures methylated cfDNA without any prior chemical treatment, which leads to easy distinguishing between cancer and non-cancer cells with high precision.
Researchers at Breast Cancer Research Foundation also developed HDSCA 3.0, the novel third-generation liquid biopsy technology, that uses five distinct biomarkers to identify and detect rare circulating cells. In addition, early-stage lung cancer detection has also observed significant advancements. For example, Biomark’s blood based metabolomic biomarker panel got clinically approved by the FDA in June 2023. The cancer biopsy market growth is certain, owing to the holistic research in developing better diagnostic solutions in cancer.
Cancer Biopsy Market Segmentation
Cancer Biopsy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product and Services
Cancer is the second most prevalent chronic illness after cardiovascular diseases in the United States, as a result, it has dominated the cancer biopsy market share in the historical period. The presence of key medical industry pioneers along with a robust infrastructure and relevant awareness on diagnostics has contributed to the market share.
During the forecast period, EU-4 is anticipated to lead the major markets as there are some major developments occurring in the region. For instance, Hungary has become a hub of artificial intelligence led technologies to detect cancer at an early stage, which is set to revolutionize the entire diagnostic market. Moreover, the Welsh government launched a new diagnostic strategy in Wales to lower the burden of lung cancer in the region.
Asia Pacific, especially Japan, is expected to witness the fastest growth which can be accredited to an intense emphasis on providing relevant awareness to the people to prevent cancer cases. Hence, the cancer biopsy market size will expand. In addition, there are several research and development initiatives to drive contemporary innovations in the field, aiding growth in upcoming years.
Cancer Biopsy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Cancer Biopsy: Introduction
Cancer Biopsy is a type of diagnostic method to detect the presence of a tumour in a body part. It is done by removing a piece of tissue or a sample of cells from the body to test externally in a lab. If cancer exists, a biopsy can help in the determination of its grade. Doctors mostly prescribe it if a patient shows underlying signs of cancer like weakness or fatigue.
After taking the tissue sample, it is sent to a laboratory where it can be chemically treated or frozen and sliced into thin sections. These sections are later placed on glass slides and studied under a microscope. There are different types of biopsies like needle biopsies, skin biopsies, endoscopic biopsies, and others.
Cancer Biopsy Market Analysis
Cancer is one of the most fatal diseases, affecting a substantial portion of the population. As there has been significant emphasis on treatment, early diagnosis plays a critical role in decreasing the number of mortalities related to it. Therefore, the cancer biopsy market demand has increased over the years.
Over the years, liquid biopsy has been a preferred method of detection when compared to conventional technology. This can be attributed to its safe, non-invasive, and easily recurring process. With a vision to expand the potential of liquid biopsy to detect and monitor cancer, researchers at the AACR annual meeting 2023 presented a study of an MCED test which utilizes a new platform to analyze DNA methylation. This new platform captures methylated cfDNA without any prior chemical treatment, which leads to easy distinguishing between cancer and non-cancer cells with high precision.
Researchers at Breast Cancer Research Foundation also developed HDSCA 3.0, the novel third-generation liquid biopsy technology, that uses five distinct biomarkers to identify and detect rare circulating cells. In addition, early-stage lung cancer detection has also observed significant advancements. For example, Biomark’s blood based metabolomic biomarker panel got clinically approved by the FDA in June 2023. The cancer biopsy market growth is certain, owing to the holistic research in developing better diagnostic solutions in cancer.
Cancer Biopsy Market Segmentation
Cancer Biopsy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product and Services
- Kits and Consumables
- Instruments
- Services
- Needle Biopsy
- Skin Biopsies
- Bone Marrow Biopsies
- Liquid Biopsies
- Other Biopsies
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Cancer is the second most prevalent chronic illness after cardiovascular diseases in the United States, as a result, it has dominated the cancer biopsy market share in the historical period. The presence of key medical industry pioneers along with a robust infrastructure and relevant awareness on diagnostics has contributed to the market share.
During the forecast period, EU-4 is anticipated to lead the major markets as there are some major developments occurring in the region. For instance, Hungary has become a hub of artificial intelligence led technologies to detect cancer at an early stage, which is set to revolutionize the entire diagnostic market. Moreover, the Welsh government launched a new diagnostic strategy in Wales to lower the burden of lung cancer in the region.
Asia Pacific, especially Japan, is expected to witness the fastest growth which can be accredited to an intense emphasis on providing relevant awareness to the people to prevent cancer cases. Hence, the cancer biopsy market size will expand. In addition, there are several research and development initiatives to drive contemporary innovations in the field, aiding growth in upcoming years.
Cancer Biopsy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- QIAGEN
- Illumina, Inc.
- ANGLE plc
- BD (Becton, Dickinson and Company)
- Bio-Rad Laboratories Inc.
- Hologic, Inc.
- BIOCEPT, INC.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Cancer Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Cancer Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Cancer Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Cancer Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Cancer Epidemiology Forecast (2018-2034)
- 5.3.2 France Cancer Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Cancer Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Cancer Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Cancer Epidemiology Forecast (2018-2034)
- 5.4 Japan Cancer Epidemiology Forecast (2018-2034)
- 6 Cancer Biopsy Market Overview – 7MM
- 6.1 Cancer Biopsy Market Historical Value (2018-2024)
- 6.2 Cancer Biopsy Market Forecast Value (2025-2034)
- 7 Cancer Biopsy Market Landscape – 7MM
- 7.1 Cancer Biopsy: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Cancer Biopsy Product Landscape
- 7.2.1 Analysis by Product & Services
- 7.2.2 Analysis by Type
- 8 Cancer Biopsy Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Cancer Biopsy Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Cancer Biopsy Market Segmentation – 7MM
- 11.1 Cancer Biopsy Market by Product and Services
- 11.1.1 Market Overview
- 11.1.2 Kits and Consumables
- 11.1.3 Instruments
- 11.1.4 Services
- 11.2 Cancer Biopsy Market by Type
- 11.2.1 Market Overview
- 11.2.2 Needle Biopsy
- 11.2.3 Skin Biopsies
- 11.2.4 Bone Marrow Biopsies
- 11.2.5 Liquid Biopsies
- 11.2.6 Other Biopsies
- 11.3 Cancer Biopsy Market by Region
- 11.3.1 Market Overview
- 11.3.2 United States
- 11.3.3 EU-4 and the United Kingdom
- 11.3.3.1 Germany
- 11.3.3.2 France
- 11.3.3.3 Italy
- 11.3.3.4 Spain
- 11.3.3.5 United Kingdom
- 11.3.4 Japan
- 12 United States Cancer Biopsy Market
- 12.1 Cancer Biopsy Market Historical Value (2018-2024)
- 12.2 Cancer Biopsy Market Forecast Value (2025-2034)
- 12.3 Cancer Biopsy Market by Type
- 12.4 Cancer Biopsy Market by Treatment Type
- 13 EU-4 and United Kingdom Cancer Biopsy Market
- 13.1 Cancer Biopsy Market Historical Value (2018-2024)
- 13.2 Cancer Biopsy Market Forecast Value (2025-2034)
- 13.3 Germany Cancer Biopsy Market Overview
- 13.3.1 Cancer Biopsy Market by Type
- 13.3.2 Cancer Biopsy Market by Treatment Type
- 13.4 France Cancer Biopsy Market Overview
- 13.4.1 Cancer Biopsy Market by Type
- 13.4.2 Cancer Biopsy Market by Treatment Type
- 13.5 Italy Cancer Biopsy Market Overview
- 13.5.1 Cancer Biopsy Market by Type
- 13.5.2 Cancer Biopsy Market by Treatment Type
- 13.6 Spain Cancer Biopsy Market Overview
- 13.6.1 Cancer Biopsy Market by Type
- 13.6.2 Cancer Biopsy Market by Treatment Type
- 13.7 United Kingdom Cancer Biopsy Market Overview
- 13.7.1 Cancer Biopsy Market by Type
- 13.7.2 Cancer Biopsy Market by Treatment Type
- 14 Japan Cancer Biopsy Market
- 14.1 Cancer Biopsy Market Historical Value (2018-2024)
- 14.2 Cancer Biopsy Market Forecast Value (2025-2034)
- 14.3 Cancer Biopsy Market by Type
- 14.4 Cancer Biopsy Market by Treatment Type
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding and Investment Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnerships and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 QIAGEN
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisitions
- 20.1.5 Certifications
- 20.2 Illumina, Inc.
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisitions
- 20.2.5 Certifications
- 20.3 ANGLE plc
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisitions
- 20.3.5 Certifications
- 20.4 BD (Becton, Dickinson and Company)
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisitions
- 20.4.5 Certifications
- 20.5 Bio-Rad Laboratories Inc.
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisitions
- 20.5.5 Certifications
- 20.6 Hologic, Inc.
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisitions
- 20.6.5 Certifications
- 20.7 BIOCEPT, INC.
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisitions
- 20.7.5 Certifications
- 20.8 Thermo Fisher Scientific, Inc.
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisitions
- 20.8.5 Certifications
- 20.9 F. Hoffmann-La Roche Ltd.
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisitions
- 20.9.5 Certifications
- 20.10 Danaher
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisitions
- 20.10.5 Certifications
- 21 Cancer Biopsy Market- Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
